Literature DB >> 19008688

Management of lower extremity peripheral arterial disease.

Andrew W Gardner1, Azhar Afaq.   

Abstract

Peripheral arterial disease (PAD), a manifestation of systemic atherosclerosis, is a significant health problem. It manifests in lower extremities as intermittent claudication, limb ischemia, or gangrene and other locations as stroke, renal failure, or mesenteric ischemia. Fontaine and Rutherford classifications are the 2 commonly used classifications to stage the severity of PAD. The diagnostic tools include ankle-brachial index, a valuable tool in diagnosing lower extremity PAD, and a treadmill test. Other useful diagnostic tools include the San Diego Claudication Questionnaire to screen patients for symptoms and imaging modalities such as duplex scan, angiogram, computer tomographic angiogram, and magnetic resonance angiogram. Medical management of PAD involves comprehensive care, including risk factor modification of etiologies predisposing to atherosclerosis. These involve using antiplatelet therapy with aspirin or clopidogrel, controlling hypertension, managing hypercholesterolemia, and using vasodilators such as cilostazol. Exercise rehabilitation is an efficacious approach to improve intermittent claudication and should be recommended to each patient. Revascularization therapy is indicated for those who have critical limb ischemia or severe claudication not improved by medical management. Revascularization consists of endovascular techniques to open up the vessel and traditional bypass surgery to bypass the diseased segment. Recent published guidelines detailing recommendations on different treatment modalities in patients with PAD are described.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19008688      PMCID: PMC2743684          DOI: 10.1097/HCR.0b013e31818c3b96

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil Prev        ISSN: 1932-7501            Impact factor:   2.081


  63 in total

1.  Effect of daily muscular exercise in patients with intermittent claudication.

Authors:  O A Larsen; N A Lassen
Journal:  Lancet       Date:  1966-11-19       Impact factor: 79.321

2.  The Framingham Study. Cigarettes and the development of intermittent claudication.

Authors:  W B Kannel; D Shurtleff
Journal:  Geriatrics       Date:  1973-02

Review 3.  The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys.

Authors:  F G Fowkes
Journal:  Int J Epidemiol       Date:  1988-06       Impact factor: 7.196

4.  Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment.

Authors:  Wilbert S Aronow; Devraj Nayak; Steven Woodworth; Chul Ahn
Journal:  Am J Cardiol       Date:  2003-09-15       Impact factor: 2.778

5.  Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs.

Authors:  A Strano; G Davi; G Avellone; S Novo; A Pinto
Journal:  Angiology       Date:  1984-07       Impact factor: 3.619

6.  Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication.

Authors:  K M Rao; D L Simel; H J Cohen; J Crawford; M S Currie
Journal:  J Lab Clin Med       Date:  1990-06

7.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

8.  Combining segmental systolic pressures and plethysmography to diagnose arterial occlusive disease of the legs.

Authors:  R B Rutherford; D H Lowenstein; M F Klein
Journal:  Am J Surg       Date:  1979-08       Impact factor: 2.565

9.  The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population.

Authors:  M H Criqui; A Fronek; M R Klauber; E Barrett-Connor; S Gabriel
Journal:  Circulation       Date:  1985-03       Impact factor: 29.690

10.  Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.

Authors:  Emile R Mohler; William R Hiatt; Mark A Creager
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

View more
  24 in total

1.  Improved detection of in-stent restenosis by blood pool agent-enhanced, high-resolution, steady-state magnetic resonance angiography.

Authors:  Christina M Plank; Florian Wolf; Herbert Langenberger; Michael Weber; Dietrich Beitzke; Alfred Stadler; Martin Schillinger; Johannes Lammer; Christian Loewe
Journal:  Eur Radiol       Date:  2011-05-10       Impact factor: 5.315

2.  A near infrared spectroscopy-based test of calf muscle function in patients with peripheral arterial disease.

Authors:  Brian Lindegaard Pedersen; Niels Bækgaard; Bjørn Quistorff
Journal:  Int J Angiol       Date:  2015-03

3.  Comparison Between Alprostadil and Iloprost in Intravenous Treatment of Patients With Chronic Peripheral Arterial Disease.

Authors:  Dan Nicolae Tesloianu; Corneliu Morosanu; Ene-Cristian Roata; Laurentiu Sorodoc
Journal:  Maedica (Bucur)       Date:  2016-09

4.  Differential impact of familial hypercholesterolemia and combined hyperlipidemia on vascular wall and network remodeling in mice.

Authors:  Phoebe A Stapleton; Adam G Goodwill; Milinda E James; Alexandre C D'Audiffret; Jefferson C Frisbee
Journal:  Microcirculation       Date:  2010-01       Impact factor: 2.628

Review 5.  Growth factors for angiogenesis in peripheral arterial disease.

Authors:  Vitali Gorenoi; Michael U Brehm; Armin Koch; Anja Hagen
Journal:  Cochrane Database Syst Rev       Date:  2017-06-08

Review 6.  Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis.

Authors:  Belinda J Parmenter; Gudrun Dieberg; Neil A Smart
Journal:  Sports Med       Date:  2015-02       Impact factor: 11.136

7.  Spontaneous and coherent anti-Stokes Raman spectroscopy of human gastrocnemius muscle biopsies in CH-stretching region for discrimination of peripheral artery disease.

Authors:  X Huang; S Irmak; Y F Lu; I Pipinos; G Casale; J Subbiah
Journal:  Biomed Opt Express       Date:  2015-07-07       Impact factor: 3.732

Review 8.  Community walking programs for treatment of peripheral artery disease.

Authors:  Ryan J Mays; R Kevin Rogers; William R Hiatt; Judith G Regensteiner
Journal:  J Vasc Surg       Date:  2013-10-05       Impact factor: 4.268

9.  Oxygen availability and skeletal muscle oxidative capacity in patients with peripheral artery disease: implications from in vivo and in vitro assessments.

Authors:  Corey R Hart; Gwenael Layec; Joel D Trinity; Yann Le Fur; Jayson R Gifford; Heather L Clifton; Russell S Richardson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-22       Impact factor: 4.733

Review 10.  Chronology of mitochondrial and cellular events during skeletal muscle ischemia-reperfusion.

Authors:  Stéphanie Paradis; Anne-Laure Charles; Alain Meyer; Anne Lejay; James W Scholey; Nabil Chakfé; Joffrey Zoll; Bernard Geny
Journal:  Am J Physiol Cell Physiol       Date:  2016-04-13       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.